Alzheimer's Disease Neurology Cancer Diagnostics Cancer Detection Genetic Testing AI in Medicine Infectious Diseases Artificial Intelligence Ultrasound Imaging Services Cardiology Cancer Diagnosis Molecular Diagnostics Dermatopathology Host-Response Technologies Artificial Intelligence in Medicine Genetic Disorders Arthritis Disease Detection Pediatric Care Neurological Disorders Neuroscience AI Diagnostics Quality Improvement Diagnostic Testing Diabetes Biotechnology Laboratory Equipment Vision Tests Pathology Cancer Imaging Agents Skin Cancer Cancer Screening Coronary Angiography Blood Tests Technology in Healthcare Cardiovascular Health Blood-Testing Technology
Want to see what podcasts are saying about this topic? Search across 165K+ podcasts. Explore Radar
The decision lets doctors switch an aromatase inhibitor to the oral SERD camizestrant after a blood test finds an ESR1 resistance mutation, with confirmatory trials required.
